
Carl J Pepine

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5272914/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2003, 290, 2805.	7.4	1,107
2	Gut Dysbiosis Is Linked to Hypertension. Hypertension, 2015, 65, 1331-1340.	2.7	1,079
3	Insights From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. Journal of the American College of Cardiology, 2006, 47, S21-S29.	2.8	727
4	Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous?. Annals of Internal Medicine, 2006, 144, 884.	3.9	664
5	Coronary Microvascular Reactivity to Adenosine Predicts Adverse Outcome in Women Evaluated for Suspected Ischemia. Journal of the American College of Cardiology, 2010, 55, 2825-2832.	2.8	660
6	Insights From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. Journal of the American College of Cardiology, 2006, 47, S4-S20.	2.8	620
7	Effects of Ranolazine With Atenolol, Amlodipine, or Diltiazem on Exercise Tolerance and Angina Frequency in Patients With Severe Chronic Angina <subtitle>A Randomized Controlled Trial</subtitle> . JAMA - Journal of the American Medical Association, 2004, 291, 309.	7.4	609
8	Transient asymptomatic S-T segment depression during daily activity. American Journal of Cardiology, 1977, 39, 396-402.	1.6	592
9	Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients With Diabetes and Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2010, 304, 61.	7.4	578
10	Ischemia and No Obstructive Coronary Artery Disease (INOCA). Circulation, 2017, 135, 1075-1092.	1.6	527
11	Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. Journal of the American College of Cardiology, 2004, 43, 1375-1382.	2.8	502
12	Adverse Cardiovascular Outcomes in Women With Nonobstructive Coronary Artery Disease. Archives of Internal Medicine, 2009, 169, 843.	3.8	475
13	Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: Results from the NHLBI WISE study. American Heart Journal, 2001, 141, 735-741.	2.7	470
14	Intramyocardial, Autologous CD34+ Cell Therapy for Refractory Angina. Circulation Research, 2011, 109, 428-436.	4.5	433
15	ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. Journal of the American College of Cardiology, 2011, 57, 2037-2114.	2.8	419
16	The gut microbiota and the brain–gut–kidney axis in hypertension and chronic kidney disease. Nature Reviews Nephrology, 2018, 14, 442-456.	9.6	413
17	Prognosis in Women With Myocardial Ischemia in the Absence of Obstructive Coronary Disease. Circulation, 2004, 109, 2993-2999.	1.6	383
18	Abnormal Myocardial Phosphorus-31 Nuclear Magnetic Resonance Spectroscopy in Women with Chest Pain but Normal Coronary Angiograms, New England Journal of Medicine, 2000, 342, 829-835.	27.0	382

#	Article	IF	CITATIONS
19	Serum Amyloid A as a Predictor of Coronary Artery Disease and Cardiovascular Outcome in Women. Circulation, 2004, 109, 726-732.	1.6	379
20	Effect of Intracoronary Delivery of Autologous Bone Marrow Mononuclear Cells 2 to 3 Weeks Following Acute Myocardial Infarction on Left Ventricular Function. JAMA - Journal of the American Medical Association, 2011, 306, 2110.	7.4	377
21	Hypertension-Linked Pathophysiological Alterations in the Gut. Circulation Research, 2017, 120, 312-323.	4.5	374
22	Effect of the Use and Timing of Bone Marrow Mononuclear Cell Delivery on Left Ventricular Function After Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2012, 308, 2380-9.	7.4	357
23	Abnormal Coronary Vasomotion as a Prognostic Indicator of Cardiovascular Events in Women. Circulation, 2004, 109, 722-725.	1.6	346
24	The Women's Ischemia Syndrome Evaluation (WISE) Study: protocol design, methodology and feasibility report. Journal of the American College of Cardiology, 1999, 33, 1453-1461.	2.8	328
25	Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure. Clinical Science, 2018, 132, 701-718.	4.3	328
26	Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression. Gut, 2018, 67, 1555.2-1557.	12.1	318
27	The Economic Burden of Angina in Women With Suspected Ischemic Heart Disease. Circulation, 2006, 114, 894-904.	1.6	299
28	Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). European Heart Journal, 2007, 29, 1327-1334.	2.2	276
29	Fifteen new risk loci for coronary artery disease highlight arterial-wall-specific mechanisms. Nature Genetics, 2017, 49, 1113-1119.	21.4	260
30	Emergence of Nonobstructive CoronaryÂArtery Disease. Journal of the American College of Cardiology, 2015, 66, 1918-1933.	2.8	257
31	Detailed angiographic analysis of women with suspected ischemic chest pain (pilot phase data from) Tj ETQq1 1	0.784314 1.6	rgBT /Over 238
32	Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: results from the NIH-NHLBI-sponsored Women's Ischaemia Syndrome Evaluation (WISE) study. European Heart Journal, 2005, 27, 1408-1415.	2.2	238
33	Mental Stress–Induced Ischemia and All-Cause Mortality in Patients With Coronary Artery Disease. Circulation, 2002, 105, 1780-1784.	1.6	228
34	Ischemic, Hemodynamic, and Neurohormonal Responses to Mental and Exercise Stress. Circulation, 1996, 94, 2402-2409.	1.6	222
35	Long-Term Observations in Patients with Angina and Normal Coronary Arteriograms. Circulation, 1973, 47, 36-43.	1.6	207
36	In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE). American Heart Journal, 2011, 162, 678-684.	2.7	185

#	Article	IF	CITATIONS
37	Cardiac Magnetic Resonance Myocardial Perfusion Reserve Index Is Reduced in Women With Coronary Microvascular Dysfunction. Circulation: Cardiovascular Imaging, 2015, 8, .	2.6	184
38	First-in-Man Study of a Cardiac Extracellular Matrix Hydrogel in Early and Late Myocardial Infarction Patients. JACC Basic To Translational Science, 2019, 4, 659-669.	4.1	183
39	Coronary flow velocity response to adenosine characterizes coronary microvascular function in women with chest pain and no obstructive coronary disease. Journal of the American College of Cardiology, 1999, 33, 1469-1475.	2.8	181
40	Safety of Coronary Reactivity Testing in Women With No Obstructive Coronary Artery Disease. JACC: Cardiovascular Interventions, 2012, 5, 646-653.	2.9	177
41	Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women. Journal of the American College of Cardiology, 2020, 75, 2602-2618.	2.8	175
42	An Intravascular Ultrasound Analysis in Women Experiencing Chest Pain in the Absence of Obstructive Coronary Artery Disease: A Substudy from the National Heart, Lung and Blood Institute–Sponsored Women's Ischemia Syndrome Evaluation (WISE). Journal of Interventional Cardiology, 2010, 23, 511-519.	1.2	162
43	Hypertension Across a Woman'sÂLifeÂCycle. Journal of the American College of Cardiology, 2018, 71, 1797-1813.	2.8	159
44	Some Thoughts on the Vasculopathy of Women With Ischemic Heart Disease. Journal of the American College of Cardiology, 2006, 47, S30-S35.	2.8	156
45	Adverse outcomes among women presenting with signs and symptoms of ischemia and no obstructive coronary artery disease: Findings from the National Heart, Lung, and Blood Institute–sponsored Women's Ischemia Syndrome Evaluation (WISE) angiographic core laboratory. American Heart Journal, 2013, 166, 134-141.	2.7	153
46	A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. European Heart Journal, 2016, 37, 1504-1513.	2.2	152
47	Impact of Abnormal Coronary Reactivity on Long-Term Clinical Outcomes inÂWomen. Journal of the American College of Cardiology, 2019, 73, 684-693.	2.8	152
48	A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. American Journal of Cardiology, 1999, 84, 46-50.	1.6	145
49	Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. Journal of the American College of Cardiology, 1998, 32, 1228-1237.	2.8	144
50	Loci influencing blood pressure identified using a cardiovascular gene-centric array. Human Molecular Genetics, 2013, 22, 1663-1678.	2.9	141
51	Altered Gut Microbiome Profile in Patients With Pulmonary Arterial Hypertension. Hypertension, 2020, 75, 1063-1071.	2.7	130
52	Left Ventricular, Peripheral Vascular, and Neurohumoral Responses to Mental Stress in Normal Middle-Aged Men and Women. Circulation, 1996, 94, 2768-2777.	1.6	127
53	The Value of Estimated Functional Capacity in Estimating Outcome. Journal of the American College of Cardiology, 2006, 47, S36-S43.	2.8	124
54	Ischemia and No Obstructive Coronary Artery Disease (INOCA): What Is the Risk?. Journal of the American Heart Association, 2018, 7, e008868.	3.7	124

#	Article	IF	CITATIONS
55	Medical Therapy for Heart Failure Caused by Ischemic Heart Disease. Circulation Research, 2019, 124, 1520-1535.	4.5	115
56	Clinical Outcomes in the Diabetes Cohort of the International Verapamil SR-Trandolapril Study. Hypertension, 2004, 44, 637-642.	2.7	114
57	Treatment of coronary microvascular dysfunction. Cardiovascular Research, 2020, 116, 856-870.	3.8	114
58	Diminazene Aceturate Enhances Angiotensin-Converting Enzyme 2 Activity and Attenuates Ischemia-Induced Cardiac Pathophysiology. Hypertension, 2013, 62, 746-752.	2.7	109
59	Assessment of Vascular Dysfunction inÂPatients Without Obstructive CoronaryÂArtery Disease. JACC: Cardiovascular Interventions, 2020, 13, 1847-1864.	2.9	105
60	Comorbid Depression and Anxiety Symptoms as Predictors of Cardiovascular Events: Results From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. Psychosomatic Medicine, 2009, 71, 958-964.	2.0	104
61	The Gut, Its Microbiome, and Hypertension. Current Hypertension Reports, 2017, 19, 36.	3.5	103
62	Mild Renal Insufficiency Is Associated With Angiographic Coronary Artery Disease in Women. Circulation, 2002, 105, 2826-2829.	1.6	101
63	Genetic Variation in <i>PEAR1</i> Is Associated With Platelet Aggregation and Cardiovascular Outcomes. Circulation: Cardiovascular Genetics, 2013, 6, 184-192.	5.1	97
64	Brain–Gut–Bone Marrow Axis. Circulation Research, 2016, 118, 1327-1336.	4.5	95
65	Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. American Journal of Cardiology, 2004, 93, 147-153.	1.6	94
66	Prognostic Value of Global MR Myocardial Perfusion Imaging in Women With Suspected Myocardial Ischemia and No Obstructive Coronary Disease. JACC: Cardiovascular Imaging, 2010, 3, 1030-1036.	5.3	94
67	Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit ⁺) Tj ETQq2	l 1 0.7843 4.5	314 rgBT /Ove
68	The Athena trials: Autologous adiposeâ€derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction. Catheterization and Cardiovascular Interventions, 2017, 89, 169-177.	1.7	89
69	Intestinal Permeability Biomarker Zonulin is Elevated in Healthy Aging. Journal of the American Medical Directors Association, 2017, 18, 810.e1-810.e4.	2.5	89
70	Microglial Cells Impact Gut Microbiota and Gut Pathology in Angiotensin II-Induced Hypertension. Circulation Research, 2019, 124, 727-736.	4.5	89
71	A Phase <scp>II</scp> study of autologous mesenchymal stromal cells and câ€kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the <scp>CCTRN CONCERTâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 661-674.	7.1	89
72	Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension, Journal of Hypertension, 2014, 32, 635-643.	0.5	88

#	Article	IF	CITATIONS
73	Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. European Heart Journal, 2009, 30, 1395-1401.	2.2	86
74	Quality and Equitable Health Care Gaps forÂWomen. Journal of the American College of Cardiology, 2017, 70, 373-388.	2.8	86
75	Coronary microvascular reactivity is only partially predicted by atherosclerosis risk factors or coronary artery disease in women evaluated for suspected ischemia: results from the NHLBI Women's Ischemia Syndrome Evaluation (WISE). Clinical Cardiology, 2007, 30, 69-74.	1.8	85
76	Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization. European Heart Journal, 2019, 40, 2455-2462.	2.2	85
77	Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group. European Heart Journal, 2021, 42, 4592-4600.	2.2	84
78	Body composition changes and cardiometabolic benefits of a balanced Italian Mediterranean Diet in obese patients with metabolic syndrome. Acta Diabetologica, 2013, 50, 409-416.	2.5	82
79	Ten-Year Mortality in the WISE Study (Women's Ischemia Syndrome Evaluation). Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	82
80	2014 Hypertension Recommendations From the Eighth Joint National Committee Panel Members Raise Concerns for Elderly Black and Female Populations. Journal of the American College of Cardiology, 2014, 64, 394-402.	2.8	79
81	Depression Symptom Severity and Reported Treatment History in the Prediction of Cardiac Risk in Women With Suspected Myocardial Ischemia. Archives of General Psychiatry, 2006, 63, 874.	12.3	74
82	Impaired Autonomic Nervous System-Microbiome Circuit in Hypertension. Circulation Research, 2019, 125, 104-116.	4.5	73
83	Impact of antibiotics on arterial blood pressure in a patient with resistant hypertension — A case report. International Journal of Cardiology, 2015, 201, 157-158.	1.7	69
84	Predictors of Development of Diabetes Mellitus in Patients With Coronary Artery Disease Taking Antihypertensive Medications (Findings from the INternational VErapamil SR-Trandolapril STudy) Tj ETQq0 0 0 rg	gBT ‡Ø verle	ock680 Tf 50 2
85	Verapamil use in patients with cardiovascular disease: An overview of randomized trials. Clinical Cardiology, 1998, 21, 633-641.	1.8	67
86	Relationship among mental stress–induced ischemia and ischemia during daily life and during exercise: the Psychophysiologic Investigations of Myocardial Ischemia (PIMI) Study. Journal of the American College of Cardiology, 1999, 33, 1476-1484.	2.8	67
87	2014 Eighth Joint National Committee Panel Recommendation for BloodÂPressureÂTargets Revisited. Journal of the American College of Cardiology, 2014, 64, 784-793.	2.8	67
88	Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data. PLoS Medicine, 2018, 15, e1002538.	8.4	67
89	Detailed Analysis of Bone Marrow From Patients With Ischemic Heart Disease and Left Ventricular Dysfunction. Circulation Research, 2014, 115, 867-874.	4.5	65
90	Bone Marrow Characteristics Associated With Changes in Infarct Size After STEMI. Circulation Research, 2015, 116, 99-107.	4.5	65

#	Article	IF	CITATIONS
91	Cardiovascular Disease and 10-Year Mortality in Postmenopausal Women with Clinical Features of Polycystic Ovary Syndrome. Journal of Women's Health, 2016, 25, 875-881.	3.3	65
92	Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Lancet, The, 2021, 398, 1803-1810.	13.7	64
93	Sex differences in chest pain in patients with documented coronary artery disease and exercise-induced ischemia: Results from the PIMI study. American Heart Journal, 2001, 142, 864-871.	2.7	63
94	Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. Journal of Hypertension, 2013, 31, 698-704.	0.5	63
95	Sustained Captoprilâ€Induced Reduction in Blood Pressure Is Associated With Alterations in Gutâ€Brain Axis in the Spontaneously Hypertensive Rat. Journal of the American Heart Association, 2019, 8, e010721.	3.7	63
96	Ankle Brachial Index Values, Leg Symptoms, and Functional Performance Among Communityâ€Dwelling Older Men and Women in the Lifestyle Interventions and Independence for Elders Study. Journal of the American Heart Association, 2013, 2, e000257.	3.7	61
97	Why names matter for women: MINOCA/INOCA (myocardial infarction/ischemia and no obstructive) Tj ETQq1 1	0.784314 1.8	rgBT /Overlo
98	Effect of Phosphodiesterase Type 5 Inhibition on Microvascular Coronary Dysfunction in Women: A Women's Ischemia Syndrome Evaluation (WISE) Ancillary Study. Clinical Cardiology, 2011, 34, 483-487.	1.8	58
99	Association Between the Chromosome 9p21 Locus and Angiographic Coronary Artery Disease Burden. Journal of the American College of Cardiology, 2013, 61, 957-970.	2.8	58
100	Autologous CD34 ⁺ Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study. Cell Transplantation, 2016, 25, 1701-1711.	2.5	58
101	Menopausal symptoms and cardiovascular disease mortality in the Women's Ischemia Syndrome Evaluation (WISE). Menopause, 2017, 24, 126-132.	2.0	58
102	Cardiovascular Therapies and Risk for Development of Diabetes. Journal of the American College of Cardiology, 2004, 44, 509-512.	2.8	57
103	Cardiovascular and Mortality Risk of Apparent Resistant Hypertension in Women With Suspected Myocardial Ischemia: A Report From the NHLBIâ€Sponsored WISE Study. Journal of the American Heart Association, 2014, 3, e000660.	3.7	57
104	ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases. Hypertension, 2020, 76, 651-661.	2.7	57
105	Age at Menarche and Risk of Cardiovascular Disease Outcomes: Findings From the National Heart Lung and Blood Institute‧ponsored Women's Ischemia Syndrome Evaluation. Journal of the American Heart Association, 2019, 8, e012406.	3.7	56
106	Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. Lancet Oncology, The, 2021, 22, 558-570.	10.7	56
107	SYNTAX Score and Long-TermÂOutcomes. Journal of the American College of Cardiology, 2017, 69, 395-403.	2.8	54
108	Perfusion, cryopreservation, and nanowarming of whole hearts using colloidally stable magnetic cryopreservation agent solutions. Science Advances, 2021, 7, .	10.3	54

#	Article	IF	CITATIONS
109	Report of the National Heart, Lung, and Blood Institute Working Group on the Role of Microbiota in Blood Pressure Regulation. Hypertension, 2017, 70, 479-485.	2.7	53
110	Inflammation in Atherosclerosis. Circulation, 2006, 113, e728-32.	1.6	52
111	Acute Stroke During Pregnancy and Puerperium. Journal of the American College of Cardiology, 2020, 75, 180-190.	2.8	52
112	Predictors of Adverse Outcome Among Patients With Hypertension and Coronary Artery Disease. Journal of the American College of Cardiology, 2006, 47, 547-551.	2.8	51
113	Rationale and design of the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD (WARRIOR) trial. American Heart Journal, 2021, 237, 90-103.	2.7	51
114	Women, Hypertension, and the Systolic Blood Pressure Intervention Trial. American Journal of Medicine, 2016, 129, 1030-1036.	1.5	50
115	Angiotensin-converting enzyme 2 inhibits high-mobility group box 1 and attenuates cardiac dysfunction post-myocardial ischemia. Journal of Molecular Medicine, 2016, 94, 37-49.	3.9	50
116	TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function. Circulation Research, 2018, 122, 479-488.	4.5	50
117	Maternal Treatment With Captopril Persistently Alters Gut-Brain Communication and Attenuates Hypertension of Male Offspring. Hypertension, 2020, 75, 1315-1324.	2.7	50
118	Migraines, Angiographic Coronary Artery Disease and Cardiovascular Outcomes in Women. American Journal of Medicine, 2006, 119, 670-675.	1.5	49
119	Does Patient-Physician Gender Concordance Influence Patient Perceptions or Outcomes?. Journal of the American College of Cardiology, 2021, 77, 1135-1138.	2.8	49
120	Management of Women With Congenital or Inherited Cardiovascular Disease From Pre-Conception Through Pregnancy andÂPostpartum. Journal of the American College of Cardiology, 2021, 77, 1778-1798.	2.8	49
121	Cardiovascular safety of NSAIDs: Additional insights after PRECISION and point of view. Clinical Cardiology, 2017, 40, 1352-1356.	1.8	48
122	A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in Patients Treated With a Calcium Antagonist Versus an Atenolol Hypertension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST). Psychosomatic Medicine, 2005, 67, 398-406.	2.0	47
123	Hypertension in pregnancy: Taking cues from pathophysiology for clinical practice. Clinical Cardiology, 2018, 41, 220-227.	1.8	47
124	Gut microbiota and serum metabolite differences in African Americans and White Americans with high blood pressure. International Journal of Cardiology, 2018, 271, 336-339.	1.7	47
125	Gender in cardiovascular medicine: chest pain and coronary artery disease. European Heart Journal, 2019, 40, 3819-3826.	2.2	47
126	Circadian Variation in Coronary Tone in Patients With Stable Angina. Circulation, 1995, 92, 3201-3205.	1.6	47

#	Article	IF	CITATIONS
127	Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease. Circulation, 2017, 135, 1417-1428.	1.6	46
128	Depression phenotype identified by using single nucleotide exact amplicon sequence variants of the human gut microbiome. Molecular Psychiatry, 2021, 26, 4277-4287.	7.9	46
129	Gut Microbiome and Neuroinflammation in Hypertension. Circulation Research, 2022, 130, 401-417.	4.5	46
130	Clinical implications of endothelial dysfunction. Clinical Cardiology, 1998, 21, 795-799.	1.8	45
131	α-Adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: Results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES). American Heart Journal, 2008, 156, 397-404.	2.7	45
132	Bone Marrow Mononuclear Cell Therapy for Acute Myocardial Infarction. Circulation Research, 2014, 114, 1564-1568.	4.5	45
133	Noninvasive Imaging toÂEvaluate Women With Stable Ischemic Heart Disease. JACC: Cardiovascular Imaging, 2016, 9, 421-435.	5.3	45
134	Heart Failure With Preserved Ejection Fraction: Is Ischemia Due to Coronary Microvascular Dysfunction a Mechanistic Factor?. American Journal of Medicine, 2019, 132, 692-697.	1.5	45
135	Butyrate Regulates COVID-19–Relevant Genes in Gut Epithelial Organoids From Normotensive Rats. Hypertension, 2021, 77, e13-e16.	2.7	45
136	Phase II Clinical Research Design in Cardiology. Circulation, 2013, 127, 1630-1635.	1.6	44
137	Inflammatory biomarkers as predictors of heart failure in women without obstructive coronary artery disease: A report from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). PLoS ONE, 2017, 12, e0177684.	2.5	43
138	Effects of angiotensin-converting enzyme inhibition on transient ischemia. Journal of the American College of Cardiology, 2003, 42, 2049-2059.	2.8	42
139	Comparison of subgroups assigned to medical regimens used to suppress cardiac ischemia (the) Tj ETQq1 1 0.7	84314 rgE 1.6	3T /Qverlock
140	Impaired Coronary Vascular Reactivity and Functional Capacity in Women. Journal of the American College of Cardiology, 2006, 47, S44-S49.	2.8	41
141	The Promise and Challenge of InducedÂPluripotent Stem Cells forÂCardiovascular Applications. JACC Basic To Translational Science, 2016, 1, 510-523.	4.1	41
142	A Microvascular-Myocardial Diastolic Dysfunctional State and Risk for Mental Stress Ischemia. JACC: Cardiovascular Imaging, 2014, 7, 362-365.	5.3	40
143	A randomized controlled trial of low-dose hormone therapy on myocardial ischemia in postmenopausal women with no obstructive coronary artery disease: Results from the National Institutes of Health/National Heart, Lung, and Blood Institute–sponsored Women's Ischemia Syndrome Evaluation (WISE). American Heart Journal, 2010, 159, 987,e1-987,e7.	2.7	39
144	Women and atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2021, 32, 2793-2807.	1.7	39

#	Article	IF	CITATIONS
145	PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. Journal of Hypertension, 2015, 33, 2278-2285.	0.5	38
146	Effects of Perhexiline on Coronary Hemodynamic and Myocardial Metabolic Responses to Tachycardia. Circulation, 1974, 49, 887-893.	1.6	37
147	Ischemic Heart Disease in Women. Journal of the American College of Cardiology, 2006, 47, S1-S3.	2.8	37
148	Late sodium channel blockade improves angina and myocardial perfusion in patients with severe coronary microvascular dysfunction: Women's Ischemia Syndrome Evaluation–Coronary Vascular Dysfunction ancillary study. International Journal of Cardiology, 2019, 276, 8-13.	1.7	37
149	Gut Microbiota. Circulation Research, 2017, 120, 1724-1726.	4.5	36
150	The Impact of Nitric Oxide in Cardiovascular Medicine: Untapped Potential Utility. American Journal of Medicine, 2009, 122, S10-S15.	1.5	35
151	Inflammation, endothelial cell activation, and coronary microvascular dysfunction in women with chest pain and no obstructive coronary artery disease. American Heart Journal, 2005, 150, 109-115.	2.7	34
152	Syndrome X and Microvascular Coronary Dysfunction. Circulation, 2011, 124, 1477-1480.	1.6	34
153	Renal Function and Coronary Microvascular Dysfunction in Women with Symptoms/Signs of Ischemia. PLoS ONE, 2015, 10, e0125374.	2.5	34
154	Aldosterone inhibition and coronary endothelial function in women without obstructive coronary artery disease: An ancillary study of the National Heart, Lung, and Blood Institute–sponsored Women's Ischemia Syndrome Evaluation. American Heart Journal, 2014, 167, 826-832.	2.7	33
155	Migraine Headache and Long-Term Cardiovascular Outcomes: An Extended Follow-Up of the Women's Ischemia Syndrome Evaluation. American Journal of Medicine, 2017, 130, 738-743.	1.5	33
156	Peripheral Blood Cytokine Levels After Acute Myocardial Infarction. Circulation Research, 2017, 120, 1947-1957.	4.5	33
157	Sex and gender differences in COVID-19: More to be learned!. American Heart Journal Plus, 2021, 3, 100011.	0.6	33
158	Management of Women With Acquired Cardiovascular Disease From Pre-Conception Through Pregnancy andÂPostpartum. Journal of the American College of Cardiology, 2021, 77, 1799-1812.	2.8	33
159	Clinical Implications of the Women's Ischemia Syndrome Evaluation: Inter-Relationships Between Symptoms, Psychosocial Factors and Cardiovascular Outcomes. Women's Health, 2013, 9, 479-490.	1.5	32
160	Pharmacogenomic Association of Nonsynonymous SNPs in <i>SIGLEC12</i> , <i>A1BG</i> , and the Selectin Region and Cardiovascular Outcomes. Hypertension, 2013, 62, 48-54.	2.7	32
161	Largeâ€5cale Gene entric Analysis Identifies Polymorphisms for Resistant Hypertension. Journal of the American Heart Association, 2014, 3, e001398.	3.7	32
162	Identification of Bone Marrow Cell Subpopulations Associated with Improved Functional Outcomes in Patients with Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial. Cell Transplantation, 2016, 25, 1675-1687.	2.5	32

#	Article	IF	CITATIONS
163	Why are women better protected from COVID-19: Clues for men? Sex and COVID-19. International Journal of Cardiology, 2020, 315, 105-106.	1.7	32
164	An injectable capillary-like microstructured alginate hydrogel improves left ventricular function after myocardial infarction in rats. International Journal of Cardiology, 2016, 220, 149-154.	1.7	31
165	A Six-Day, Lifestyle-Based Immersion Program Mitigates Cardiovascular Risk Factors and Induces Shifts in Gut Microbiota, Specifically Lachnospiraceae, Ruminococcaceae, Faecalibacterium prausnitzii: A Pilot Study. Nutrients, 2021, 13, 3459.	4.1	31
166	Influence of smoking status on progression of endothelial dysfunction. Clinical Cardiology, 1998, 21, 331-334.	1.8	30
167	One-Year Follow-up of Intracoronary Stem Cell Delivery on Left Ventricular Function Following ST-Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2014, 311, 301.	7.4	30
168	Association of aortic stiffness and wave reflections with coronary flow reserve in women without obstructive coronary artery disease: An ancillary study from the National Heart, Lung, and Blood Institute–sponsored Women's Ischemia Syndrome Evaluation (WISE). American Heart Journal, 2015, 170, 1243-1254.	2.7	30
169	Multiple Causes for Ischemia Without Obstructive Coronary Artery Disease. Circulation, 2015, 131, 1044-1046.	1.6	30
170	Hypertension-linked mechanical changes of rat gut. Acta Biomaterialia, 2016, 45, 296-302.	8.3	29
171	Heart failure hospitalization in women with signs and symptoms of ischemia: A report from the women's ischemia syndrome evaluation study. International Journal of Cardiology, 2016, 223, 936-939.	1.7	28
172	Impact of Selection Bias on Estimation of Subsequent Event Risk. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	28
173	Prevalence, Causes, and Predictors of 30â€Day Readmissions Following Hospitalization With Acute Myocardial Infarction Complicated By Cardiogenic Shock: Findings From the 2013–2014 National Readmissions Database. Journal of the American Heart Association, 2018, 7, .	3.7	28
174	Enhancing clinical trials on the internet: Lessons from INVEST. Clinical Cardiology, 2009, 24, V-17-V-23.	1.8	27
175	Anxiety associations with cardiac symptoms, angiographic disease severity, and healthcare utilization: The NHLBI-sponsored Women's Ischemia Syndrome Evaluation. International Journal of Cardiology, 2013, 168, 2335-2340.	1.7	27
176	Adverse Pregnancy Conditions, Infertility, and Future Cardiovascular Risk: Implications for Mother and Child. Cardiovascular Drugs and Therapy, 2015, 29, 391-401.	2.6	27
177	Microvascular coronary dysfunction and ischemic heart disease: Where are we in 2014?. Trends in Cardiovascular Medicine, 2015, 25, 98-103.	4.9	27
178	Resistant Hypertension: Mechanisms and Treatment. Current Hypertension Reports, 2017, 19, 56.	3.5	27
179	Predictors of Change in Physical Function in Older Adults in Response to Long-Term, Structured Physical Activity: The LIFE Study. Archives of Physical Medicine and Rehabilitation, 2017, 98, 11-24.e3.	0.9	27
180	Magnitude of and Characteristics Associated With the Treatment of Calcium Channel Blocker–Induced Lower-Extremity Edema With Loop Diuretics. JAMA Network Open, 2019, 2, e1918425.	5.9	27

#	Article	IF	CITATIONS
181	Introduction. American Journal of Cardiology, 2006, 97, 1-3.	1.6	26
182	Phytoestrogens and Lipoproteins in Women. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2209-2213.	3.6	26
183	Rethinking Stable Ischemic Heart Disease. Journal of the American College of Cardiology, 2012, 60, 957-959.	2.8	26
184	Efficacy and Safety of Angiotensin Receptor Blockers in Older Patients: A Meta-Analysis of Randomized Trials. American Journal of Hypertension, 2015, 28, 576-585.	2.0	26
185	Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC), BMI Open, 2019, 9, e028698.	1.9	26
186	Effects of propranolol on coronary hemodynamic and metabolic responses to tachycardia stress in patients with and without coronary disease. Catheterization and Cardiovascular Diagnosis, 1977, 3, 47-57.	0.3	25
187	Endothelium as a Predictor of Adverse Outcomes. Clinical Cardiology, 2010, 33, 730-732.	1.8	25
188	Increased wave reflection and ejection duration in women with chest pain and nonobstructive coronary artery disease. Journal of Hypertension, 2013, 31, 1447-1455.	0.5	25
189	Long-Term Mortality in Hypertensive Patients With Coronary Artery Disease. Hypertension, 2016, 68, 1110-1114.	2.7	25
190	Systemic hypertension and coronary artery disease. American Journal of Cardiology, 1998, 82, 21-24.	1.6	24
191	Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy HeartÂFailure Patients. JACC: CardioOncology, 2020, 2, 581-595.	4.0	24
192	Introduction: New and emerging implications for the field of vascular biology. American Journal of Cardiology, 2003, 91, 1-2.	1.6	23
193	Residual risk for secondary ischemic events in patients with atherothrombotic disease: Opportunity for future improvements in patient care. Annals of Medicine, 2010, 42, 19-35.	3.8	23
194	TIMI Frame Count and Adverse Events in Women with No Obstructive Coronary Disease: A Pilot Study from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE). PLoS ONE, 2014, 9, e96630.	2.5	23
195	Depression, Dietary Habits, and Cardiovascular Events Among Women with Suspected Myocardial Ischemia. American Journal of Medicine, 2014, 127, 840-847.	1.5	23
196	Myocardial Scar Is Prevalent and Associated With Subclinical Myocardial Dysfunction in Women With Suspected Ischemia But No Obstructive Coronary Artery Disease. Circulation, 2018, 137, 874-876.	1.6	23
197	Migraine Headache: An Underâ€Appreciated Risk Factor for Cardiovascular Disease in Women. Journal of the American Heart Association, 2019, 8, e014546.	3.7	23
198	Maternal Stroke. Circulation, 2021, 143, 727-738.	1.6	23

#	Article	IF	CITATIONS
199	Myocardial tissue deformation is reduced in subjects with coronary microvascular dysfunction but not rescued by treatment with ranolazine. Clinical Cardiology, 2017, 40, 300-306.	1.8	22
200	The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post–myocardial infarction heart failure: Trial rationale and study design. American Heart Journal, 2018, 201, 141-148.	2.7	22
201	Prevalence of Coronary Endothelial and Microvascular Dysfunction in Women with Symptoms of Ischemia and No Obstructive Coronary Artery Disease Is Confirmed by a New Cohort: The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation–Coronary Vascular Dysfunction (WISE-CVD), Iournal of Interventional Cardiology, 2019, 2019, 1-8.	1.2	22
202	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Circulation Genomic and Precision Medicine, 2019, 12, e002471.	3.6	22
203	Sex and Race/Ethnicity Differences in Atrial Fibrillation. Journal of the American College of Cardiology, 2019, 74, 2812-2815.	2.8	22
204	Microvascular Dysfunction as a Systemic Disease: A Review of the Evidence. American Journal of Medicine, 2022, 135, 1059-1068.	1.5	22
205	A population-based evaluation of the thrombolysis in myocardial infarction risk score for unstable angina and non-ST elevation myocardial infarction. Clinical Cardiology, 2004, 27, 74-78.	1.8	21
206	Usefulness of Beta Blockade in Contemporary Management of Patients With Stable Coronary Heart Disease. American Journal of Cardiology, 2014, 114, 1607-1612.	1.6	21
207	Diagnostic Cardiovascular Imaging and Therapeutic Strategies in Pregnancy. Journal of the American College of Cardiology, 2021, 77, 1813-1822.	2.8	21
208	The Prognostic and Economic Implications of a Strategy to Detect and Treat Asymptomatic Ischemia: The Atenolol Silent Ischemia Trial (ASIST) Protocol. Clinical Cardiology, 1991, 14, 457-462.	1.8	20
209	Comparison of Effects of Nisoldipine-Extended Release and Amlodipine in Patients With Systemic Hypertension and Chronic Stable Angina Pectoris. American Journal of Cardiology, 2003, 91, 274-279.	1.6	20
210	Combining Psychosocial Data to Improve Prediction of Cardiovascular Disease Risk Factors and Events. Psychosomatic Medicine, 2012, 74, 263-270.	2.0	20
211	Social Participation Modifies the Effect of a Structured Physical Activity Program on Major Mobility Disability Among Older Adults: Results From the LIFE Study. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2018, 73, 1501-1513.	3.9	20
212	Transcriptomic signature of gut microbiome-contacting cells in colon of spontaneously hypertensive rats. Physiological Genomics, 2020, 52, 121-132.	2.3	20
213	The effects of angiotensin-converting enzyme inhibition on endothelial dysfunction: potential role in myocardial ischemia. American Journal of Cardiology, 1998, 82, 23S-27S.	1.6	19
214	Sudden Cardiac Death in Women With Suspected Ischemic Heart Disease, Preserved Ejection Fraction, and No Obstructive Coronary Artery Disease: A Report From the Women's Ischemia Syndrome Evaluation Study. Journal of the American Heart Association, 2017, 6, .	3.7	19
215	Myocardial ischemia: From disease to syndrome. International Journal of Cardiology, 2020, 314, 32-35.	1.7	19
216	Functional heart recovery in an adult mammal, the spiny mouse. International Journal of Cardiology, 2021, 338, 196-203.	1.7	19

#	Article	IF	CITATIONS
217	The Serpin Solution; Targeting Thrombotic and Thrombolytic Serine Proteases in Inflammation. Cardiovascular & Hematological Disorders Drug Targets, 2013, 13, 99-110.	0.7	19
218	Identification of a Gut Commensal That Compromises the Blood Pressure-Lowering Effect of Ester Angiotensin-Converting Enzyme Inhibitors. Hypertension, 2022, 79, 1591-1601.	2.7	19
219	Diagnostic tests for tricuspid insufficiency: How good?. Catheterization and Cardiovascular Diagnosis, 1979, 5, 1-6.	0.3	18
220	Percutaneous brachial catheterization using a modified sheath and new catheter system. Catheterization and Cardiovascular Diagnosis, 1984, 10, 637-642.	0.3	18
221	Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial. American Heart Journal, 2016, 179, 142-150.	2.7	18
222	Stem cell therapy restores viscoelastic properties of myocardium in rat model of hypertension. Journal of the Mechanical Behavior of Biomedical Materials, 2016, 59, 71-77.	3.1	18
223	Circulating Biomarkers to Identify Responders in Cardiac Cell therapy. Scientific Reports, 2017, 7, 4419.	3.3	18
224	Heart failure with preserved ejection fraction: Similarities and differences between women and men. International Journal of Cardiology, 2020, 304, 101-108.	1.7	18
225	Predicted Versus Observed Major Adverse Cardiac Event Risk in Women With Evidence of Ischemia and No Obstructive Coronary Artery Disease: A Report From WISE (Women's Ischemia Syndrome) Tj ETQq1 1 0.784	431 4 angBT /	/Ov es lock 10 1
226	Effects of perhexiline on symptomatic and hemodynamic responses to exercise in patients with angina pectoris. American Journal of Cardiology, 1974, 33, 806-812.	1.6	17
227	Plasma nitroglycerin concentrations and hemodynamic effects of sublingual, ointment, and controlled-release forms of nitroglycerin. Clinical Pharmacology and Therapeutics, 1984, 36, 765-772.	4.7	17
228	Mental Stress and Myocardial Ischemia: Young Women at Risk. Journal of the American Heart Association, 2016, 5, .	3.7	17
229	Dynapenia and Metabolic Health in Obese and Nonobese Adults Aged 70ÂYears and Older: The LIFE Study. Journal of the American Medical Directors Association, 2017, 18, 312-319.	2.5	17
230	Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial. American Heart Journal, 2018, 201, 54-62.	2.7	17
231	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circulation Genomic and Precision Medicine, 2019, 12, e002470.	3.6	17
232	Characteristics of contemporary patients with hypertension and coronary artery disease. Clinical Cardiology, 2004, 27, 571-576.	1.8	16
233	Coronary Angiography. Circulation, 2013, 127, 1760-1762.	1.6	16
234	Identification of cardiovascular risk factors associated with bone marrow cell subsets in patients with STEMI: a biorepository evaluation from the CCTRN TIME and LateTIME clinical trials. Basic Research in Cardiology, 2017, 112, 3.	5.9	16

#	Article	IF	CITATIONS
235	Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD. American Journal of Medicine, 2018, 131, 1463-1472.e7.	1.5	16
236	Genome-wide association analysis of common genetic variants of resistant hypertension. Pharmacogenomics Journal, 2019, 19, 295-304.	2.0	16
237	Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: An individual participant data meta-analysis. PLoS Medicine, 2021, 18, e1003599.	8.4	16
238	Ischemic heart disease: Metabolic approaches to management. Clinical Cardiology, 2004, 27, 439-441.	1.8	15
239	Mild renal dysfunction and long-term adverse outcomes in women with chest pain: Results from the National Heart, Lung, and Blood Institute–sponsored Women's Ischemia Syndrome Evaluation (WISE). American Heart Journal, 2015, 169, 412-418.	2.7	15
240	Genetic loci associated with nonobstructive coronary artery disease in Caucasian women. Physiological Genomics, 2016, 48, 12-20.	2.3	15
241	Psychosocial predictors of long-term mortality among women with suspected myocardial ischemia: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. Journal of Behavioral Medicine, 2016, 39, 687-693.	2.1	15
242	Genetic Variants Associated With Uncontrolled Blood Pressure onÂThiazide Diuretic/βâ€Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses)Âand INVEST (International Verapamilâ€SR Trandolapril Study) Trials. Journal of the American Heart Association, 2017, 6, .	3.7	15
243	Hypertension in Florida: Data From the OneFlorida Clinical Data Research Network. Preventing Chronic Disease, 2018, 15, E27.	3.4	15
244	Incidence, prevalence, and predictors of treatmentâ€resistant hypertension with intensive blood pressure lowering. Journal of Clinical Hypertension, 2019, 21, 825-834.	2.0	15
245	Design, methodology and baseline characteristics of the Women's Ischemia Syndrome Evaluation–Coronary Vascular Dysfunction (WISE-CVD). American Heart Journal, 2020, 220, 224-236.	2.7	15
246	Depressive hypertension: A proposed human endotype of brain/gut microbiome dysbiosis. American Heart Journal, 2021, 239, 27-37.	2.7	15
247	Demonstration of an inadvertently created aorto-coronary venous anastomosis: Evidence against the clinical effectiveness of retrograde coronary venous perfusion. Catheterization and Cardiovascular Diagnosis, 1979, 5, 367-370.	0.3	14
248	Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women's Heart Disease. Journal of Women's Health, 2016, 25, 996-1003.	3.3	14
249	Influence of smoking status on angiotensin-converting enzyme inhibition-related improvement in coronary endothelial function. TREND Investigators. Trial on Reversing Endothelial Dysfunction. Cardiovascular Drugs and Therapy, 1999, 13, 201-209.	2.6	13
250	What Is the Optimal Blood Pressure and Drug Therapy for Patients With Coronary Artery Disease?. JAMA - Journal of the American Medical Association, 2004, 292, 2271.	7.4	13
251	The vascular biology of hypertension and atherosclerosis and intervention with calcium antagonists and angiotensin-converting enzyme inhibitors. Clinical Cardiology, 2001, 24, V-1-V-5.	1.8	13
252	Effects of Pharmacologic Therapy on Health-Related Quality of Life in Elderly patients with Atrial Fibrillation: A systematic Review of Randomized and Nonrandomized Trials. Clinical Medicine Insights: Cardiology, 2013, 7, CMC.S10628.	1.8	13

#	Article	IF	CITATIONS
253	Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasibility results from CardiAMP heart failure roll-in cohort. International Journal of Cardiology, 2021, 326, 131-138.	1.7	13
254	Acute Pulmonary Embolism During Pregnancy and Puerperium. Mayo Clinic Proceedings, 2021, 96, 2102-2113.	3.0	13
255	Acetylcholine versus cold pressor testing for evaluation of coronary endothelial function. PLoS ONE, 2017, 12, e0172538.	2.5	13
256	Specialized Proresolving Mediators in Symptomatic Women With Coronary Microvascular Dysfunction (from the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD [WARRIOR]) Tj ETQq0 C	01r.gBT /O	verbock 10 Tf
257	Ischemia and no obstructive coronary arteries in patients with stable ischemic heart disease. International Journal of Cardiology, 2022, 348, 1-8.	1.7	13
258	Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. Stem Cells Translational Medicine, 2022, 11, 688-703.	3.3	13
259	A New Temporary Atrial Pacing Catheter Inserted Percutaneously into the Subclavian Vein Without Fluoroscopy: A Preliminary Report. PACE - Pacing and Clinical Electrophysiology, 1981, 4, 458-463.	1.2	12
260	Nicardipine, a new calcium channel blocker: Role for vascular selectivity. Clinical Cardiology, 1989, 12, 240-246.	1.8	12
261	Calcium antagonists in the treatment of coronary artery disease. Current Opinion in Pharmacology, 2013, 13, 301-308.	3.5	12
262	Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. Pharmacogenetics and Genomics, 2013, 23, 697-705.	1.5	12
263	Resting coronary velocity and myocardial performance in women with impaired coronary flow reserve: Results from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction (WISE-CVD) study. International Journal of Cardiology, 2020, 309, 19-22.	1.7	12
264	Aspirin in Primary Prevention: What Changed? A Critical Appraisal of Current Evidence. American Journal of Cardiology, 2021, 141, 38-48.	1.6	12
265	Left ventricular circumferential strain and coronary microvascular dysfunction: A report from the Women's Ischemia Syndrome Evaluation Coronary Vascular Dysfunction (WISE-CVD) Project. International Journal of Cardiology, 2021, 327, 25-30.	1.7	12
266	Efficacy of Ranolazine for Treatment of Coronary Microvascular Dysfunction—A Systematic Review and Meta-analysis of Randomized Trials. CJC Open, 2021, 3, 101-108.	1.5	12
267	Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center. Cardio-Oncology, 2021, 7, 10.	1.7	12
268	Enhancing the Function of CD34+ Cells by Targeting Plasminogen Activator Inhibitor-1. PLoS ONE, 2013, 8, e79067.	2.5	12
269	Detailed analysis of polymer response to delivery balloon expansion of drug-eluting stents versus bare metal stents. EuroIntervention, 2013, 9, 389-397.	3.2	12
270	Angina pectoris in a contemporary population: characteristics and therapeutic implications. TIDES Investigators. Cardiovascular Drugs and Therapy, 1998, 12, 211-216.	2.6	11

#	Article	IF	CITATIONS
271	Optimizing lipid management in patients with acute coronary syndromes. American Journal of Cardiology, 2003, 91, 30-35.	1.6	11
272	A degradable, bioactive, gelatinized alginate hydrogel to improve stem cell/growth factor delivery and facilitate healing after myocardial infarction. Medical Hypotheses, 2012, 79, 673-677.	1.5	11
273	Simple Integer Risk Score to Determine Prognosis of Patients With Hypertension and Chronic Stable Coronary Artery Disease. Journal of the American Heart Association, 2013, 2, e000205.	3.7	11
274	Circulating progenitor cells and coronary microvascular dysfunction: Results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation – Coronary Vascular Dysfunction Study (WISE-CVD). Atherosclerosis, 2016, 253, 111-117.	0.8	11
275	CES1P1 variant â``816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril. European Journal of Clinical Pharmacology, 2016, 72, 681-687.	1.9	11
276	Intracoronary Bolus Injection Versus Intravenous Infusion of Adenosine for Assessment of Coronary Flow Velocity Reserve in Women With Signs and Symptoms of Myocardial Ischemia and No Obstructive Coronary Artery Disease. JACC: Cardiovascular Interventions, 2018, 11, 2125-2127.	2.9	11
277	Left ventricular concentric remodelling and functional impairment in women with ischaemia with no obstructive coronary artery disease and intermediate coronary flow reserve: a report from the WISE-CVD study. European Heart Journal Cardiovascular Imaging, 2019, 20, 875-882.	1.2	11
278	Adverse Pregnancy Outcomes Are Associated with Reduced Coronary Flow Reserve in Women With Signs and Symptoms of Ischemia Without Obstructive Coronary Artery Disease: A Report from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction Study. Journal of Women's Health, 2020, 29, 487-492.	3.3	11
279	Association of Factor V Leiden With Subsequent Atherothrombotic Events. Circulation, 2020, 142, 546-555.	1.6	11
280	Immune Dysregulation in HFpEF: A Target for Mesenchymal Stem/Stromal Cell Therapy. Journal of Clinical Medicine, 2020, 9, 241.	2.4	11
281	A multiplexed ion-exchange membrane-based miRNA (MIX·miR) detection platform for rapid diagnosis of myocardial infarction. Lab on A Chip, 2021, 21, 3876-3887.	6.0	11
282	Coronary endothelial dysfunction appears to be a manifestation of a systemic process: A report from the Women's Ischemia Syndrome Evaluation – Coronary Vascular Dysfunction (WISE-CVD) study. PLoS ONE, 2021, 16, e0257184.	2.5	11
283	Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial. JMIR Research Protocols, 2017, 6, e255.	1.0	11
284	Ergonovine testing for coronary artery spasm in patients with angiographic mitral valve prolapse. Catheterization and Cardiovascular Diagnosis, 1978, 4, 265-274.	0.3	10
285	Antagonist molecules in the treatment of angina. Expert Opinion on Pharmacotherapy, 2013, 14, 2323-2342.	1.8	10
286	Relationships between components of metabolic syndrome and coronary intravascular ultrasound atherosclerosis measures in women without obstructive coronary artery disease. Cardiovascular Endocrinology, 2015, 4, 45-52.	0.8	10
287	Unanticipated Cardiotoxicity Associated with Targeted Anticancer Therapy in Patients with Hematologic Malignancies Patients: Natural History and Risk Factors. Cardiovascular Toxicology, 2018, 18, 184-191.	2.7	10
288	Not All Stem Cells Are Created Equal. Circulation Research, 2018, 123, 944-946.	4.5	10

#	Article	IF	CITATIONS
289	Coronary Vascular Function and Cardiomyocyte Injury. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 3015-3021.	2.4	10
290	Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations. American Heart Journal, 2021, 241, 38-49.	2.7	10
291	Brachial Artery Constriction during Brachial Artery Reactivity Testing Predicts Major Adverse Clinical Outcomes in Women with Suspected Myocardial Ischemia: Results from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. PLoS ONE, 2013, 8, e74585.	2.5	9
292	Comparison of low and high dose intracoronary adenosine and acetylcholine in women undergoing coronary reactivity testing: Results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). International Journal of Cardiology, 2014, 172, e114-e115.	1.7	9
293	Assessing cardiovascular risk in women: Looking beyond traditional risk factors. Trends in Cardiovascular Medicine, 2015, 25, 152-153.	4.9	9
294	β ₂ â€Adrenergic Receptor Gene Affects the Heart Rate Response of βâ€Blockers: Evidence From 3 Clinical Studies. Journal of Clinical Pharmacology, 2019, 59, 1462-1470.	2.0	9
295	Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 645122.	2.4	9
296	Syndrome of Nonobstructive Coronary Artery Diseases: A Comprehensive Overview of Open Artery Ischemia. American Journal of Medicine, 2021, 134, 1321-1329.	1.5	9
297	Does the Brain Know When the Heart Is Ischemic?. Annals of Internal Medicine, 1996, 124, 1006.	3.9	9
298	Echocardiographic analysis of systolic and diastolic left ventricular wall motion during transient myocardial ischemia. Journal of Clinical Ultrasound, 1981, 9, 59-65.	0.8	8
299	A Critical Analysis of Clinical Outcomes Reported in Stem Cell Trials for Acute Myocardial Infarction: Some Thoughts for Design of Future Trials. Current Atherosclerosis Reports, 2013, 15, 341.	4.8	8
300	Some thoughts on the continuing dilemma of angina pectoris. European Heart Journal, 2014, 35, 1361-1364.	2.2	8
301	Experimental and early investigational drugs for angina pectoris. Expert Opinion on Investigational Drugs, 2016, 25, 1413-1421.	4.1	8
302	Fertility Therapy and Long-Term Cardiovascular Risk. Journal of the American College of Cardiology, 2017, 70, 1214-1215.	2.8	8
303	Beneficial Effects of Angiotensin-(1–7) on CD34+ Cells From Patients With Heart Failure. Journal of Cardiovascular Pharmacology, 2018, 71, 155-159.	1.9	8
304	Would Repurposing Minocycline Alleviate Neurologic Manifestations of COVID-19?. Frontiers in Neuroscience, 2020, 14, 577780.	2.8	8
305	Peak Systolic Blood Pressure During the Exercise Test: Reference Values by Sex and Age and Association With Mortality. Hypertension, 2021, 77, 1906-1914.	2.7	8
306	Factors Influencing Clinical Outcomes After Revascularization in the Asymptomatic Cardiac Ischemia Pilot (ACIP). Journal of Cardiac Surgery, 1999, 14, 1-8.	0.7	7

#	Article	IF	CITATIONS
307	Combination Rosuvastatin Plus Fenofibric Acid in a Cohort of Patients 65 Years or Older With Mixed Dyslipidemia: Subanalysis of Two Randomized, Controlled Studies. Clinical Cardiology, 2010, 33, 609-619.	1.8	7
308	Impact of Aspirin According to Type of Stable Coronary Artery Disease: Insights from a Large International Cohort. American Journal of Medicine, 2015, 128, 137-143.	1.5	7
309	Typical angina is associated with greater coronary endothelial dysfunction but not abnormal vasodilatory reserve. Clinical Cardiology, 2017, 40, 886-891.	1.8	7
310	Commentary - The ISCHEMIA trial. International Journal of Cardiology, 2020, 304, 1-4.	1.7	7
311	Evaluation of the key prescription sequence symmetry analysis assumption using the calcium channel blocker: Loop diuretic prescribing cascade. Pharmacoepidemiology and Drug Safety, 2022, 31, 72-81.	1.9	7
312	The effects of angiotensin-converting enzyme inhibition on endothelial dysfunction: Potential role in myocardial ischemia. American Journal of Cardiology, 1998, 82, S23-S27.	1.6	6
313	Phytoestrogens and Coronary Microvascular Function in Women with Suspected Myocardial Ischemia: A Report from the Women's Ischemia Syndrome Evaluation (WISE) Study. Journal of Women's Health, 2007, 16, 481-488.	3.3	6
314	Cardiovascular Care for Women: The 10-Q Report and Beyond. American Journal of Cardiology, 2013, 112, S2.	1.6	6
315	Angina treatments and prevention of cardiac events: an appraisal of the evidence: TableÂ1. European Heart Journal Supplements, 2015, 17, G10-G18.	0.1	6
316	The Coronary Microcirculation in STEMI: The Next Frontier?. European Heart Journal, 2015, 36, 3178-3181.	2.2	6
317	Predictors of short- and long-term mortality in hospitalized veterans with elevated troponin. Journal of Hospital Medicine, 2016, 11, 773-777.	1.4	6
318	Left ventricular mass and myocardial scarring in women with hypertensive disorders of pregnancy. Open Heart, 2020, 7, e001273.	2.3	6
319	Even "WISE-R?â€â€"an Update on the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation. Current Atherosclerosis Reports, 2020, 22, 35.	4.8	6
320	Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genomeâ€Wide Interaction Metaâ€Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies. Clinical Pharmacology and Therapeutics, 2021, 110, 723-732.	4.7	6
321	Recommendations for nomenclature and definition of cell products intended for human cardiovascular use. Cardiovascular Research, 2022, 118, 2428-2436.	3.8	6
322	International prospective cohort study of microvascular angina – Rationale and design. IJC Heart and Vasculature, 2020, 31, 100630.	1.1	6
323	Body weight and physical fitness in women with ischaemic heart disease: does physical fitness contribute to our understanding of the obesity paradox in women?. European Journal of Preventive Cardiology, 2022, 29, 1608-1614.	1.8	6
324	Comparison of the effects of nitroprusside and nitroglycerin on coronary size. Catheterization and Cardiovascular Diagnosis, 1983, 9, 391-399.	0.3	5

#	Article	IF	CITATIONS
325	How Do We Best Treat Patients With Ischemic Heart Disease?. Circulation, 1998, 98, 1985-1986.	1.6	5
326	Task force 2: Investigator participation in clinical research. Journal of the American College of Cardiology, 2004, 44, 1729-1736.	2.8	5
327	Mortality Implications of Angina and Blood Pressure in Hypertensive Patients With Coronary Artery Disease: New Data From Extended Followâ€up of the International Verapamil/Trandolapril Study (<scp>INVEST</scp>). Clinical Cardiology, 2013, 36, 442-447.	1.8	5
328	Number and Function of Bone-Marrow Derived Angiogenic Cells and Coronary Flow Reserve in Women without Obstructive Coronary Artery Disease: A Substudy of the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE). PLoS ONE, 2013, 8, e81595.	2.5	5
329	Intensive blood pressure lowering reduces adverse cardiovascular outcomes among patients with highâ€normal glucose: An analysis from the Systolic Blood Pressure Intervention Trial database. Journal of Clinical Hypertension, 2018, 20, 620-624.	2.0	5
330	Mortality implications of lower DBP with lower achieved systolic pressures in coronary artery disease. Journal of Hypertension, 2018, 36, 419-427.	0.5	5
331	Long-term mortality and estimated functional capacity among women with symptoms of ischemic heart disease: From the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. American Heart Journal, 2018, 206, 123-126.	2.7	5
332	Systolic blood pressure, heart rate, and outcomes in patients with coronary disease and heart failure. ESC Heart Failure, 2020, 7, 124-130.	3.1	5
333	Cardiovascular Considerations for the Internist and Hospitalist in the COVID-19 Era. American Journal of Medicine, 2020, 133, 1254-1261.	1.5	5
334	Clinical Safety Profile of Transendocardial Catheter Injection Systems: A Plea for Uniform Reporting. Cardiovascular Revascularization Medicine, 2021, 22, 100-108.	0.8	5
335	Potential of Minocycline for Treatment of Resistant Hypertension. American Journal of Cardiology, 2021, 156, 147-149.	1.6	5
336	Coronary Microvascular Dysfunction in Patients with Non-Obstructive Coronary Arteries: Current Gaps and Future Directions. Drugs, 2022, 82, 241-250.	10.9	5
337	Medicare Bundled Payment Policy on Anemia Care, Major Adverse Cardiovascular Events, and Mortality among Adults Undergoing Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 851-860.	4.5	5
338	Potential Role of Angiotensin onverting Enzyme Inhibition in Myocardial Ischemia and Current Clinical Trials. Clinical Cardiology, 1997, 20, II-58.	1.8	4
339	Plasma Volume Changes With an Acute Bout of High-Intensity Exercise in Men With Chronic Congestive Heart Failure Secondary to Coronary Artery Disease. American Journal of Cardiology, 1998, 81, 509-513.	1.6	4
340	Antihypertensive properties of a highâ€dose combination of trandolapril and verapamilâ€6R. Blood Pressure, 2007, 16, 6-9.	1.5	4
341	Microvascular dysfunction: what have we learned from WISE?. Expert Review of Cardiovascular Therapy, 2011, 9, 1491-1494.	1.5	4
342	Lack of association of the HMGA1 IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort. Journal of Translational Medicine, 2013, 11, 12.	4.4	4

#	Article	IF	CITATIONS
343	Effects of Verapamil SR and Atenolol on 24-Hour Blood Pressure and Heart Rate in Hypertension Patients with Coronary Artery Disease: An International Verapamil SR-Trandolapril Ambulatory Monitoring Substudy. PLoS ONE, 2015, 10, e0122726.	2.5	4
344	Safety of Routine Invasive Versus Selective Invasive Therapy in Women with Non-ST-Elevation Acute Coronary Syndrome. Cardiology and Therapy, 2016, 5, 43-50.	2.6	4
345	Advancements in pharmacotherapy for angina. Expert Opinion on Pharmacotherapy, 2017, 18, 457-469.	1.8	4
346	Effect of Lowâ€Furanocoumarin Hybrid Grapefruit Juice Consumption on Midazolam Pharmacokinetics. Journal of Clinical Pharmacology, 2017, 57, 305-311.	2.0	4
347	Extent of coronary atherosclerosis and arterial remodelling in women: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. Cardiovascular Diagnosis and Therapy, 2018, 8, 405-413.	1.7	4
348	Optimal medical treatment of hypertension in patients with coronary artery disease. Expert Review of Cardiovascular Therapy, 2018, 16, 815-823.	1.5	4
349	Statin Use for Atherosclerotic Cardiovascular Disease Prevention Among Sexual Minority Adults. Journal of the American Heart Association, 2020, 9, e018233.	3.7	4
350	Temporal Trends in Angina, Myocardial Perfusion, and Left Ventricular Remodeling in Women With No Obstructive Coronary Artery Disease Over 1‥ear Followâ€Up: Results From WISE VD. Journal of the American Heart Association, 2020, 9, e016305.	3.7	4
351	The Clinical Spectrum of Myocardial Infarction and Ischemia With Nonobstructive Coronary Arteries in Women. JACC: Cardiovascular Imaging, 2021, 14, 1053-1062.	5.3	4
352	Phytoestrogen blood levels and adverse outcomes in women with suspected ischemic heart disease. European Journal of Clinical Nutrition, 2021, 75, 829-835.	2.9	4
353	Preparticipation Cardiac Evaluation Findings in a Cohort of Collegiate Female Athletes. American Journal of Cardiology, 2021, 140, 134-139.	1.6	4
354	Prior Oral Contraceptive Use and Longer Term Mortality Outcomes in Women with Suspected Ischemic Heart Disease. Journal of Women's Health, 2021, 30, 377-384.	3.3	4
355	Distinct Gene Expression Profiles in Colonic Organoids from Normotensive and the Spontaneously Hypertensive Rats. Cells, 2021, 10, 1523.	4.1	4
356	Somatic versus cognitive depressive symptoms as predictors of coronary artery disease among women with suspected ischemia: The women's ischemia syndrome evaluation. Heart and Mind (Mumbai, India), 2021, 5, 112.	0.6	4
357	Effects of transient regional ischemia on left ventricular diastolic function. Journal of Clinical Ultrasound, 1980, 8, 233-238.	0.8	3
358	A modified catheter system for retrograde left ventricular catheterization in aortic valve stenosis. Catheterization and Cardiovascular Diagnosis, 1985, 11, 433-439.	0.3	3
359	Hemodynamic effects of high versus low-osmolar contrast media for ventriculography in severe aortic stenosis. CardioVascular and Interventional Radiology, 1988, 11, 10-13.	2.0	3
360	Working group 1: How to increase the output of cardiologists. Journal of the American College of Cardiology, 2004, 44, 233-237.	2.8	3

#	Article	IF	CITATIONS
361	Implementation of Cardovascular Cell Therapy Network trials: challenges, innovation and lessons learned from experience in the CCTRN. Expert Review of Cardiovascular Therapy, 2013, 11, 1495-1502.	1.5	3
362	Acute Kidney Injury after Transcatheter Aortic Valve Replacement. American Journal of Nephrology, 2015, 41, 370-371.	3.1	3
363	Recognizing Sex SimilaritiesÂin Cardiovascular Disease Research. Journal of the American College of Cardiology, 2015, 65, 2152-2153.	2.8	3
364	Ischemic Predictors of Outcomes in Women With Signs and Symptoms of Ischemia and Nonobstructive Coronary Artery Disease. JAMA Cardiology, 2016, 1, 491.	6.1	3
365	Aortic flow conditions predict ejection efficiency in the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Cardiovascular Diagnosis and Therapy, 2017, 7, 288-295.	1.7	3
366	Maladaptive left ventricular remodeling in women: An analysis from the Women's Ischemia Syndrome Evaluation–Coronary Vascular Dysfunction study. International Journal of Cardiology, 2018, 268, 230-235.	1.7	3
367	Reproductive lifespan and incident stroke risk among post-menopausal women: Is it time for sex-specific risk prediction tools?. International Journal of Cardiology, 2021, 328, 218-219.	1.7	3
368	Concomitant coronary microvascular dysfunction and spontaneous coronary artery dissection resulting in ST-segment elevation myocardial infarction. Journal of Cardiology Cases, 2022, 25, 76-78.	0.5	3
369	Invasive Functional Assessment in Patients With Angina and Coronary Microvascular Dysfunction. Journal of the American College of Cardiology, 2020, 75, 2550-2552.	2.8	3
370	N-Terminal pro-B-type natriuretic peptide and coronary microvascular dysfunction in women with preserved ejection fraction: A report from the Women's Ischemia Syndrome Evaluation–Coronary Vascular Dysfunction (WISE-CVD) study. PLoS ONE, 2020, 15, e0243213.	2.5	3
371	RNA Virus Gene Signatures Detected in Patients With Cardiomyopathy After Chemotherapy; A Pilot Study. Frontiers in Cardiovascular Medicine, 2022, 9, 821162.	2.4	3
372	Factors Influencing Clinical Outcomes After Revascularization in the Asymptomatic Cardiac Ischemia Pilot (ACIP). Echocardiography, 1985, 2, 1-8.	0.9	2
373	Identifying high yield sources of patients with coronary artery disease for clinical trials: Lessons from the asymptomatic cardiac ischemia pilot (ACIP) experience. Clinical Cardiology, 1998, 21, 177-182.	1.8	2
374	Myocardial Ischemia as a Target for Treatment of Patients With Chronic Coronary Artery Disease. ACC Current Journal Review, 1998, 7, 23-27.	0.1	2
375	Digital assessment of the epicardial electrocardiogram: Novel methodology for a core laboratory for clinical studies. Clinical Cardiology, 1999, 22, 311-315.	1.8	2
376	Commentary on "New and Emerging Theories of Cardiovascular Disease― Biological Research for Nursing, 2004, 6, 17-20.	1.9	2
377	Subliminal editorial conundra confounding publication of multicenter trials. American Journal of Cardiology, 2004, 94, 1268-1269.	1.6	2
378	Introduction: The European INVESTigators meeting. Clinical Cardiology, 2001, 24, A6-A6.	1.8	2

#	Article	IF	CITATIONS
379	SENSITIVITY AND SPECIFICITY OF CMRI FOR DIAGNOSIS OF MICROVASCULAR CORONARY DYSFUNCTION IN WOMEN WITH SIGNS AND SYMPTOMS OF ISCHEMIA AND NO OBSTRUCTIVE CORONARY ARTERY DISEASE: RESULTS FROM THE NHLBI-SPONSORED WOMEN'S ISCHEMIA SYNDROME EVALUATION (WISE). Journal of the American College of Cardiology, 2013, 61, E825.	2.8	2
380	The Editor's Roundtable: The 10Q Report—Advancing Women's Heart Health Through Improved Research, Diagnosis, and Treatment. American Journal of Cardiology, 2013, 112, 1676-1687.	1.6	2
381	A training program in cardiovascular cell-based therapy: from the NHLBI Cardiovascular Cell Therapy Research Network. Regenerative Medicine, 2014, 9, 793-797.	1.7	2
382	The Prevalence of Microvascular Dysfunction, Its Role Among Men, and Links With Adverse Outcomes. Circulation, 2014, 129, 2497-2499.	1.6	2
383	Cardiac Cell Therapy Evolving From Complex to Straightforward. Circulation Research, 2017, 121, 1116-1118.	4.5	2
384	Cold Pressor Stress Cardiac Magnetic Resonance Myocardial Flow Reserve Is Not Useful for Detection of Coronary Endothelial Dysfunction in Women with Signs and Symptoms of Ischemia and No Obstructive CAD. PLoS ONE, 2017, 12, e0169818.	2.5	2
385	Redefining Resistant Hypertension. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e005979.	2.2	2
386	Sex Differences, Aspirin, and Primary Prevention. American Journal of Medicine, 2021, 134, 9-10.	1.5	2
387	Management of Cardiovascular Disease in Kidney Disease Study: Rationale and Design. American Journal of Nephrology, 2021, 52, 36-44.	3.1	2
388	Clinician engagement in the ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and) Tj ETQqO	0 0 rgBT / 1.6	Overlock 10
389	What Is the Role of Assessing Ischemia to Optimize Therapy and Outcomes for Patients with Stable Angina and Non-obstructed Coronary Arteries?. Cardiovascular Drugs and Therapy, 2022, 36, 1027-1038.	2.6	2
390	First and recurrent events in the ISCHEMIA trial: two sides of the same coin. European Heart Journal, 2021, , .	2.2	2
391	Association of coronary microvascular dysfunction and cardiac bridge integrator 1, a cardiomyocyte dysfunction biomarker. Clinical Cardiology, 2021, 44, 1586-1593.	1.8	2
392	STROKE OUTCOME IN HYPERTENSIVE CAD PATIENTS TREATED WITH VERAPAMIL SR- (VE) AND ATENOLOL-(AT) BASED STRATEGIES. Journal of Hypertension, 2004, 22, S114.	0.5	2
393	Association between High Endocardial Unipolar Voltage and Improved Left Ventricular Function in Patients with Ischemic Cardiomyopathy. Texas Heart Institute Journal, 2016, 43, 291-296.	0.3	2
394	Use of bio-informatics assessment schema (BIAS) to improve diagnosis and prognosis of myocardial perfusion data: results from the NHLBI-sponsored women's ischemia syndrome evaluation (WISE).	1.7	2

	Cardiovascular Diagnosis and Therapy, 2016, 6, 424-431.			
395	Benefit of One Week Immersion in Lifestyle-based Program for Sustainable Improvements in Cardiovascular Risk Factors Over Time. International Journal of Disease Reversal and Prevention, 2019, 2, 10.	0.1	2	
396	Stem and Progenitor Cell Therapies for Cardiovascular Disease. Journal of Cell Science & Therapy,	0.3	2	

2011, 2, .

#	Article	IF	CITATIONS
397	Relationship of Psychological Characteristics to Daily Life Ischemia. Psychosomatic Medicine, 2022, Publish Ahead of Print, .	2.0	2
398	Non-obstructive Plaque and Treatment of INOCA: More to Be Learned. Current Atherosclerosis Reports, 2022, 24, 681-687.	4.8	2
399	The effects of ACE inhibition on ischemic cardiac events: Pump failure, reinfarction, hospitalization for angina, and ventricular tachyarrhythmias. Clinical Cardiology, 1995, 18, I-26-I-33.	1.8	1
400	Clinical and detailed angiographic findings in patients with ambulatory electrocardiographic ischemia without critical coronary narrowing: Results from the asymptomatic cardiac ischemia pilot (ACIP) study. Clinical Cardiology, 1998, 21, 86-92.	1.8	1
401	President's Page: Continuing investment in "State-of-the-Art―physician education— an ACCF program of high net worth. Journal of the American College of Cardiology, 2004, 43, 313-314.	2.8	1
402	Insulin as a Cardiovascular Therapeutic: Improving Glycemic Control in Patients With Coronary Artery Disease. Journal of the American College of Cardiology, 2009, 53, S1-S2.	2.8	1
403	Bone marrow-derived cells and hypertension. Expert Review of Cardiovascular Therapy, 2010, 8, 1139-1148.	1.5	1
404	Loci influencing blood pressure identified using a cardiovascular gene-centric array. Human Molecular Genetics, 2013, 22, 3394-3395.	2.9	1
405	Reply to â€~Resistant hypertension revisited. Journal of Hypertension, 2014, 32, 1547.	0.5	1
406	Reply. Journal of the American College of Cardiology, 2016, 67, 2088.	2.8	1
407	Blood pressure, heart rate, and double product. Journal of Hypertension, 2017, 35, 1785-1786.	0.5	1
408	Serotonin Transporter Gene Polymorphism in Women With Suspected Ischemia. , 2018, 2, 8-15.	0.8	1
409	Advances in small-molecule therapy for managing angina pectoris in the elderly. Expert Opinion on Pharmacotherapy, 2019, 20, 1471-1481.	1.8	1
410	Risk and Blood Pressure Control Rates Across the Spectrum of Coronary Artery Disease in Hypertensive Women: An Analysis from The INternational VErapamil SR-Trandolapril STudy (INVEST). Journal of Women's Health, 2020, 29, 158-166.	3.3	1
411	Optimal systolic blood pressure and reduced long-term mortality in older hypertensive women with prior coronary events – An analysis from INVESTâ~†. International Journal of Cardiology: Hypertension, 2020, 7, 100052.	2.2	1
412	A Cardio-Obstetric Approach toÂManagement of the Complex Pregnant Cardiac Patient. JACC: Case Reports, 2020, 2, 86-90.	0.6	1
413	Reply to "Angiotensin-converting enzyme 2, sex differences, and COVID-19: The missing linkâ€. International Journal of Cardiology, 2021, 328, 250.	1.7	1
414	Effectiveness of sacubitril/valsartan versus aldosterone antagonists in heart failure with reduced ejection fraction: A retrospective cohort study. Pharmacotherapy, 2021, 41, 710-721.	2.6	1

#	Article	IF	CITATIONS
415	Peripheral Blood Biomarkers Associated With Improved Functional Outcome in Patients With Chronic Left Ventricular Dysfunction: A Biorepository Evaluation of the FOCUS-CCTRN Trial. Frontiers in Cardiovascular Medicine, 2021, 8, 698088.	2.4	1
416	Task Force 2: Investigator Participation in Clinical Research. Circulation, 2004, 110, 2517-2524.	1.6	1
417	What is the Real Message of the ISCHEMIA Trial from a Clinician's Perspective?. European Cardiology Review, 2020, 15, e63.	2.2	1
418	Ethnicity and blood pressure control in patients with diabetes and coronary artery disease. American Journal of Hypertension, 2002, 15, A194.	2.0	0
419	Education: Nationally achievable solutions. Clinical Cornerstone, 2004, 6, 65-70.	0.7	0
420	President's page: members' benevolence stretches the ACC mission well beyond U.S. borders. Journal of the American College of Cardiology, 2004, 43, 711-712.	2.8	0
421	President's page: fellow physicians: read, respond, repeat. Journal of the American College of Cardiology, 2004, 43, 891-892.	2.8	0
422	President's page: strengthening our house of cardiology. Journal of the American College of Cardiology, 2004, 43, 1721-1722.	2.8	0
423	President's page: Cardiology without borders: Embracing a healthy global association. Journal of the American College of Cardiology, 2004, 44, 1137-1138.	2.8	0
424	Response to The J-Point Revisited. Hypertension, 2008, 51, .	2.7	0
425	Response to Letter by Barrios and Escobar. Stroke, 2009, 40, .	2.0	0
426	Does expanded artificial intelligence improve the prognostic value of myocardial perfusion imaging? A report from the NHLBI-sponsored women's ischemia syndrome evaluation (WISE). Journal of Cardiovascular Magnetic Resonance, 2013, 15, P273.	3.3	0
427	126 CHROMOSOME 9P21 LOCUS AND ANGIOGRAPHIC CORONARY ARTERY DISEASE BURDEN: A COLLABORATIVE META-ANALYSIS. Heart, 2013, 99, A75.1-A75.	2.9	0
428	Update in Cardiology: Evidence Published in 2013. Annals of Internal Medicine, 2014, 160, 847.	3.9	0
429	CORONARY MICROVASCULAR DYSFUNCTION IS RELATED TO LEFT VENTRICULAR CONCENTRIC REMODELING AND DIASTOLIC DYSFUNCTION: FROM THE WISE-CVD STUDY. Journal of the American College of Cardiology, 2017, 69, 141.	2.8	0
430	GLOBAL LONGITUDINAL STRAIN IN PATIENTS WITH NEW LEFT VENTRICULAR SYSTOLIC DYSFUNCTION AFTER ANTICANCER TARGETED THERAPIES. Journal of the American College of Cardiology, 2017, 69, 821.	2.8	0
431	CARDIOMYOPATHY ASSOCIATED WITH TARGETED ANTICANCER THERAPIES IN ELECTRONIC HEALTH RECORDS. Journal of the American College of Cardiology, 2017, 69, 925.	2.8	0
432	PROGNOSTIC RISK FACTORS FOR HEART FAILURE HOSPITALIZATION IN WOMEN WITHOUT OBSTRUCTIVE CORONARY DISEASE: AN ANCILLARY STUDY FROM THE WOMEN'S ISCHEMIA SYNDROME EVALUATION (WISE). Journal of the American College of Cardiology, 2017, 69, 960.	2.8	0

#	Article	IF	CITATIONS
433	RELATIONSHIP BETWEEN DIASTOLIC BLOOD PRESSURE AND ALL-CAUSE MORTALITY WITH LOWER SYSTOLIC BLOOD PRESSURE AMONG HYPERTENSIVE PATIENTS WITH CORONARY ARTERY DISEASE: LONG-TERM FOLLOW-UP OF THE US COHORT OF THE INTERNATIONAL VERAPAMIL SR-TRANDOLAPRIL STUDY (INVEST). Journal of the American College of Cardiology, 2017, 69, 1685.	2.8	0
434	Systolic blood pressure target: Have we identified the optimal target yet?. Journal of Public Health and Emergency, 2017, 1, 61-61.	4.4	0
435	Predicted Versus Observed Major Adverse Cardiac Event Risk in Women with Evidence of Ischemia and No Obstructive Coronary Artery Disease: A Report from Women's Ischemia Syndrome Evaluation (WISE). Canadian Journal of Cardiology, 2018, 34, e15.	1.7	0
436	The Reply. American Journal of Medicine, 2018, 131, e73.	1.5	0
437	High sensitivity cardiac troponin T and I and risk stratification of patients with stable CHD: Is it time to incorporate this in routine clinical practice?. International Journal of Cardiology, 2018, 250, 266-267.	1.7	0
438	Regenerative Medicine in the State of Florida: Letter Outlining the Florida Organization for Regenerative Medicine. Stem Cells Translational Medicine, 2018, 7, 511-512.	3.3	0
439	Hypertension in Ischemic Heart Disease. , 2018, , 288-297.		0
440	Complementary Embryonic and Adult Cell Populations Enhance Myocardial Repair in Rat Myocardial Injury Model. Stem Cells International, 2019, 2019, 1-11.	2.5	0
441	Thiazide Exposure and Cardiovascular Risk in Type 2 Diabetes Mellitus. Hypertension, 2020, 75, e2-e5.	2.7	0
442	Depletion of Esteraseâ€Harboring Bacteria Increases Antihypertensive Efficacy of ACE Inhibitor Quinapril. FASEB Journal, 2021, 35, .	0.5	0
443	Relationship between coronary function testing and migraine: results from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction project. , 2021, 5, .		0
444	TRANDOLAPRIL IMPROVES CV OUTCOMES AND DECREASES RISK FOR NEW DIABETES IN HYPERTENSIVE PATIENTS WITH CAD. Journal of Hypertension, 2004, 22, S276.	0.5	0
445	DOGMA DISPUTED. Journal of Hypertension, 2004, 22, S113.	0.5	0
446	A "Paper-less―Study on Optimal Treatment Strategies for Hypertension and CAD: Pilot Phase Data From the INternational VErapamil-trandolapril STudy (INVEST). Journal of the American College of Cardiology, 1998, 31, 211A-212A.	2.8	0
447	Abstract 15465: Precision Medicine Approach to Resistant Hypertension: Genetic Markers of Resistant Hypertension Through a Genome-wide Association Study (GWAS) in the Secondary Prevention of Subcortical Strokes (SPS3). Circulation, 2015, 132, .	1.6	0
448	Abstract 108: Impact of a Wireless "Wearable" Device to Measure Daily Activity in Patients With Coronary Microvascular Disease Treated With Late Na Channel Inhibition (ranolazine): a Substudy of the RWISE Clinical Trial. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	0
449	Abstract 987: Unanticipated cardiotoxicity due to targeted anti-cancer therapy in hematologic malignancies patients: Natural history and risk factors. , 2017, , .		0

450 Cardiovascular Risks of Impaired Fertility and Assisted Reproductive Therapy. , 2018, , 79-88.

#	Article	IF	CITATIONS
451	Myocardial Infarction and Persistent Angina With No Obstructive Coronary Artery Disease. JACC: Case Reports, 2020, 2, 9-14.	0.6	0
452	Cell Therapy Strategies With No Safety Concerns and Demonstrated Benefits Warrant Study. Circulation Journal, 2020, 84, 2120-2121.	1.6	0
453	Abstract 16457: Racial/Ethnic Differences in Cardiac Surveillance Evaluation for Cancer Patients Treated With Anthracycline-based Chemotherapy: The Oneflorida Clinical Research Consortium. Circulation, 2020, 142, .	1.6	0
454	Coronary microvascular dysfunction as a chronic inflammatory state: Is there a role for omega-3 fatty acid treatment?. American Heart Journal Plus, 2022, 13, 100098.	0.6	0
455	Endothelial dysfunction and its role in the cycle of cardiovascular disease. Canadian Journal of Cardiology, 1998, 14 Suppl D, 5D-7D.	1.7	0
456	Angiotensin-converting enzyme inhibitors in patients with atherosclerosis and preserved left ventricular function: clinical outcomes. Canadian Journal of Cardiology, 1998, 14 Suppl D, 23D-26D.	1.7	0
457	Digital health intervention in patients with recent hospitalization for acute heart failure: A systematic review and meta-analysis of randomized trials. International Journal of Cardiology, 2022, , .	1.7	0
458	Abstract 13833: Cardiac Sympathetic Denervation in Patients With Ventricular Tachycardia or Electrical Storm: A 6 Months Follow-Up. Circulation, 2021, 144, .	1.6	0
459	Abstract 9697: Relation Between Measures of Ventricular Volume/Pressure and Myocardial Damage and Coronary Microvascular Dysfunction Response to Ranolazine. Circulation, 2021, 144, .	1.6	Ο